March 13, 2017 Leo 0Comment

Source: Access Pharmaceuticals, Inc.ACCESS PHARMACEUTICALS, INC. signed a joint development agreement with bioRASI, a full-service global CRO specializing in the accelerated development of novel therapeutics to facilitate the clinical development of the cobalamin-based oral insulin and other cobalamin-based products. One focus of this program is a first-in-man study for oral insulin Access ‘ product. Different animal species.t step in obtaining human confirmation of the significant oral bioavailability in Access ‘ Cobalamin oral insulin formulations.

About Access:Access Pharmaceuticals is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access ‘ products include ProLindac, currently. In Phase II clinical trials of patients with ovarian cancer and MuGard for the management of patients with mucositis The company also has other advanced drug delivery technologies including Cobalamin-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which provided both pre-clinical and clinical evidence has activity in certain cancers.Grit stone being an internationally recognized researcher in the field of women’s mental health and depression VCU , which examined such as depression affect women of their service life and the impact menstrual cycle and postmenopausal on depression and its treatment.

The United States depression as about twice as common in women as in men. Greater than 20 % of women depressed depression during their lives, and depression seems be affected by reproductive event, like the menstrual cycle, the postpartum period and postmenopausal.

The study revealed that women took Pristiq shown significant improvement in, as comprising measured by the 17-point Hamilton Depression Rating Scale and other physiological test.